I. Rocher

发表

Healthcare-associated bloodstream infections secondary to a urinary focus: the Québec provincial surveillance results.

C. Quach, É. Fortin, I. Rocher, 2012 .

Evaluation of the Reporting Validity of Central Line–Associated Bloodstream Infection Data to a Provincial Surveillance Program

D. Buckeridge, M. Pai, R. Platt, 2013, Infection Control & Hospital Epidemiology.

Hemodynamic and pharmacokinetic study of tertatolol in patients with alcoholic cirrhosis and portal hypertension.

S. Urien, J. Vinel, P. Calès, 1993, Journal of hepatology.

Variation in serum binding of tertatolol mediated by disease-induced modification of alpha-acid glycoprotein concentration

S. Urien, J. Tillement, I. Rocher, 2004, European Journal of Clinical Pharmacology.

Binding of indapamide to serum proteins and erythrocytes.

S. Urien, J. Tillement, P. Riant, 1988, Biochemical Pharmacology.

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.

D. Menzies, I. Rocher, C. Valiquette, 2003, American journal of respiratory and critical care medicine.

Central Line–Associated Bloodstream Infection in Neonatal Intensive Care Units

C. Quach, É. Fortin, I. Rocher, 2013, Infection Control & Hospital Epidemiology.

The impact of smoking on adherence to treatment for latent tuberculosis infection

I. Rocher, P. Brassard, C. Steensma, 2006, BMC public health.

Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity

A. Halabi, I. Rocher, C. Efthymiopoulos, 1990, Cardiovascular Drugs and Therapy.

A survey of Preventive Measures Used and their Impact on Central Line-Associated Bloodstream Infections (CLABSI) in Intensive Care Units (SPIN-BACC)

M. Kaouache, C. Quach, É. Fortin, 2013, BMC Infectious Diseases.

The Booster Effect in Two-Step Tuberculin Testing among Young Adults in Montreal

R Menzies, B. Vissandjée, I. Rocher, 1994, Annals of Internal Medicine.

Factors associated with compliance in treatment of tuberculosis.

B. Vissandjée, I. Rocher, R. Menzies, 1993, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Structure-activity relationships as a response to the pharmacological differences in beta-receptor ligands.

I. Rocher, C. Labrid, O. Guery, 1989, American journal of hypertension.

Surveillance Provinciale des Infections Nosocomiales (SPIN) Program: implementation of a mandatory surveillance program for central line-associated bloodstream infections.

D. Buckeridge, M. Pai, R. Platt, 2011, American journal of infection control.

Stereoselective binding of tertatolol and of 4-hydroxytertatolol to human plasma proteins

P. Jolliet, S. Urien, J. Tillement, 1992, European Journal of Drug Metabolism and Pharmacokinetics.

Survey of Infection Control Practices in Hemodialysis Units: Preventing Vascular Access–Associated Bloodstream Infections

M. Kaouache, C. Quach, É. Fortin, 2014, Infection Control & Hospital Epidemiology.

Epidemiology of central line-associated bloodstream infections in Quebec intensive care units: a 6-year review.

D. Buckeridge, R. Platt, C. Quach, 2012, American journal of infection control.

Tertatolol in chronic renal failure. A pharmacokinetic study.

M. Rainfray, A. Meyrier, I. Rocher, 1989, American journal of hypertension.

In closely monitored patients, adherence in the first month predicts completion of therapy for latent tuberculosis infection.

K. Schwartzman, D. Menzies, I. Rocher, 2005, The International Journal of Tuberculosis and Lung Disease.

The effect of antacid and aspirin on the bioavailability of isofezolac in man.

I. Rocher, B. Flouvat, J. Henry, 1984, International journal of clinical pharmacology, therapy, and toxicology.